What Is the Cancer Research of Prem Vaisnava;Explain?
Question by Kevin7: What is the cancer research of Prem Vaisnava;explain?
Best answer:
Answer by H????? ?oi 416™
*Vaishnava
A scientific team that includes a Kettering University physics professor is working to unlock the next major advancement in cancer research in the United States.
Kettering professor Prem Vaishnava has been spending long days in the labs of Wayne State University with hopes that the group’s research — along with work at other universities — will help bring a cancer therapy that would ideally only target cancer zones. Chemotherapy and radiation attack the entire body, which also kills regular cells.
No nausea. No loss of hair. No wipe-out fatigue.
“It’s like tailor-made medicine,” Vaishnava said.
The team is studying new uses of nanomedicine, which includes the concept of using heat to kill cancer cells in specific areas, such as the kidney or liver.
For some patients, the worst part of cancer is treatment, Vaishnava said.
The recovery from the often harsh and aggressive chemotherapy and radiation can be especially challenging depending on age and health.
“When people go through chemo or radiation, they lose their hair and eyebrows,” he said. “They can become sick, weak and vulnerable to other diseases like pneumonia.
“These are horrible side effects, so horrible some people die from them instead of the cancer itself.”
Targeted drug-delivery through nanomedicine, or destroying cancer cells through hyperthermia, has been delved into for years and parts of Europe already use the technology.
Limited forms of the technology are already used for certain cancers in the United States and there are some clinical trials being run on more advance methods.
The scientists at Wayne State are looking to unravel the method’s largest challenge so far — how to most effectively inject the medicine.
Because of the varying shapes, sizes and volumes of tumors, each person would need a different type of drug distribution, Vaishnava said.
Wayne is among several universities in the country using funding from the National Cancer Institute to study the technology.
“The delivery of therapies using nanoparticle technology approaches is very promising,” said Piotr Grodzinski, director of National Cancer Institute Alliance for nanotechnology in cancer at NCI, which spends $ 25-$ 50 million for research on cancer applications a year.
“It should improve the effectiveness of treatment, lower the side effects and may allow us to deliver drugs to areas that are difficult to deliver to (such as the brain).”
“What is clear is that it will take people of different disciplines working together.”
Vaishnava joins a handful of professors at Kettering who have been tapped for research that directly or indirectly is connected to cancer. He recently presented a paper on the Wayne State research at a conference for the European Society of Hyperthermic Oncology in Denmark.
He said even if the treatment doesn’t completely kill off a tumor or cancer cells, it could make the area more receptive to chemotherapy.
The technology could also open the door to better treating Glioblastoma multiforme, the most aggressive type of brain tumor that is nearly untreatable because of its location and the brain tissues’ resistance to letting medicine through.
“This is a very dreadful disease,” Vaishnava said. “As a scientist, that’s my passion to do something challenging that could help a lot of people suffering from it.
“Hyperthermia scientists dream they will be able to treat cancer purely by hyperthermia. In that case there would be zero side effects. It’s not a magic bullet but eventually it could be.”
http://www.mlive.com/news/flint/index.ssf/2011/11/kettering_university_professor_7.html
Current Projects include:
• Characterization of Polymer Coated Magnetic Nanoparticles for Targeted Treatment of Cancer
The objective of this project is to develop and characterize a targeted drug delivery system capable of the controlled release of chemotherapy to treat malignant tumors. Our system consists of a magnetic core with a thermo sensitive polymer p-(N-isopropylacrylamide, PNIPAM) shell. The advantage of this system is that a magnetic field can be used for targeting the system as well as to induce heat for hyperthermia treatment. Furthermore, the drug can be loaded into the PNIPAM layer and released when the temperature reaches its lower critical solution temperature (LCST) of about 45 degree Celsius. Drug release studies will be used to characterize the thermo responsive properties of the sample. Cellular uptake and cytotoxicity studies will also performed to determine in vitro behavior. Our PNIPAM-magnetic nanoparticle presents a unique and effective method of treating many cancers while reducing the deleterious effects associated with traditional drug delivery methods.
http://www.linkedin.com/pub/prem-vaishnava/8/1/74a
Japan Study Find Standard Chemotherapy Still Best Hope for Mesothelioma
The long-standing chemotherapy combination of cisplatin and pemetrexed will remain the front-line treatment regimen for mesothelioma patients in the foreseeable future, despite recent efforts to develop newer and more effective drugs. Nothing better …
Read more on Asbestos.com
North Korea's new drug addiction
A North Korean guard post, seen from a South Korean observation tower in Paju near the Demilitarized Zone dividing the two Koreas, on December 23, 2011. Reports of rampant recreational drug use of amidon are trickling out of the country. (Prakash …
Read more on GlobalPost
Older criminals present challenges for prisons, courts
Older prison inmates are more likely to have chronic illnesses and mental conditions that require special treatment, and moving them through the court system can be a complicated balancing act on the scales of justice. At the Bucks County Correctional …
Read more on The Intelligencer
First Drug in 50 years to Treat Lupus Released — For more news visit ? http://english.ntdtv.com Follow us on Twitter ? http://twitter.com/NTDTelevision Add us on Facebook ? http://facebook.com/NTDTelevision…
Find More Drug Treatment News 2011 Information…